Bruce Jackson

Ryan Zimmerman

Joshua Jennings

Kristen Kluska

Vernon Bernardino

Josh Jennings

Ramakanth Swayampakula

- Humacyte, Inc. announced the pricing of an oversubscribed registered direct offering, expecting to generate approximately **$60.0 million** in gross proceeds before fees and expenses.  **[1818382_0001104659-25-097591_tm2528189d1_ex99-1.htm:0]** 
- The offering involves the sale of **28,436,018 shares** of common stock and warrants to purchase an equal number of shares.  **[1818382_0001104659-25-097591_tm2528189d1_ex99-1.htm:0]** 
- The purchase price for one share of common stock and one warrant is **$2.11**.  **[1818382_0001104659-25-097591_tm2528189d1_ex99-1.htm:0]** 
- The warrants will become exercisable **180 days** following issuance, have an exercise price of **$2.11 per share**, and will expire on **April 7, 2031**.  **[1818382_0001104659-25-097591_tm2528189d1_ex99-1.htm:0]** 
- The offering is expected to close on or about **October 8, 2025**.  **[1818382_0001104659-25-097591_tm2528189d1_ex99-1.htm:0]**

Humacyte announces pricing of $60.0 million registered direct offering

- Humacyte announced the publication of **positive long-term results** for its Symvess product, used to treat wartime vascular trauma injuries in Ukraine.  **[1818382_d4f9a544fe844a4f89a3e2f6913cac3c_0]** 
- The study, published in *Military Medicine*, reported a **continued high rate of patency (87.1%)**, **100% limb salvage**, and **zero cases of conduit infection** in 17 patients followed for up to **18 months**.  **[1818382_d4f9a544fe844a4f89a3e2f6913cac3c_0]** 
- Patients treated with Symvess experienced **zero deaths, zero amputations, and zero infections** at both 30 days and up to **18 months** of follow-up.  **[1818382_d4f9a544fe844a4f89a3e2f6913cac3c_1]** 
- Symvess, an acellular tissue engineered vessel, is designed for **immediate off-the-shelf availability**, which is critical for wartime situations.  **[1818382_d4f9a544fe844a4f89a3e2f6913cac3c_0]** 
- The FDA approved Humacyte's Biologics License Application for ATEV in the vascular trauma indication in **December 2024**.  **[1818382_d4f9a544fe844a4f89a3e2f6913cac3c_3]**

Humacyte Announces Positive Long-Term Results for Symvess in Wartime Trauma

- Humacyte, Inc. (HUMA) and its subsidiary, Humacyte Global, Inc., entered into **Amendment No. 2 to the Revenue Interest Purchase Agreement** on **September 17, 2025**.  **[1818382_0001104659-25-090963_tm2526406d1_ex10-1.htm:0]** **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]** 
- The company will make a **$50.0 million repayment** under the Purchase Agreement, funded from existing restricted cash.  **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]** 
- This amendment removes the obligation to maintain **$50.0 million of restricted cash**, unless the Purchase Agreement is not fully repaid by **December 31, 2025**, in which case **$12.5 million** will be required.  **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]** 
- Humacyte now has the option to exercise its call option at a discounted repurchase price of **$95.5 million** if exercised on or prior to **December 31, 2025**.  **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]** **[1818382_0001104659-25-090963_tm2526406d1_ex10-1.htm:37]** 
- Up to **$7.5 million** of this call option may be satisfied through the issuance of the company's common stock.  **[1818382_0001104659-25-090963_tm2526406d1_8k.htm:1]**

Humacyte (HUMA)